Dr. Henry Adewoye, has been appointed to the newly created position of chief medical officer, Compugen Ltd. Dr. Adewoye brings more than two decades of extensive experience in leading multiple clinical trials in oncology and hematology in both the biopharmaceutical industry and academia. Dr. Adewoye will play a key role in leading the company’s transition into a clinical stage company and will assume overall responsibility of its clinical stage pipeline. Dr. Adewoye will be based at Compugen’s South San Francisco facilities and will report to Dr. Anat Cohen-Dayag, Compugen’s president and chief executive officer as part of the  senior management team.
 
Anat Cohen-Dayag, Ph.D., president and chief executive officer of Compugen said, “We are pleased to welcome Henry to Compugen’s management team as we advance our pipeline of product candidates into the clinic. We look forward to benefiting from Henry’s extensive clinical drug development expertise and his contributions to the development of our first-in-class therapeutics targeting significant unmet medical needs of patients suffering from a variety of cancers.”
 
Dr. Adewoye joins the company from Gilead Sciences Inc., where he most recently served as clinical director in Oncology Clinical Research and was on the Oncology Leadership Team for multiple Phase I-III Programs (Idelalisib, a PI3 kinase delta inhibitor approved for relapsed CLL, SLL and Follicular lymphoma), Andecaliximab (MMP-9 inhibitor), GS-9901, and Acalisib. Prior to Gilead, he was clinical research medical director in Oncology at Amgen and global medical monitor for the initial registrational trial of the bispecific antibody blinatumomab (Blincyto) and several Phase II and III studies evaluating VEGF inhibitors (motesanib, trebananib) in patients with solid tumors.